Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines

Viruses

Angela Berzi²  Norbert Varga³  Sara Sattin³  Patrizio Antonazzo¹  Mara Biasin²  Irene Cetin¹  Daria Trabattoni²  Anna Bernardi³ 

[1] Unit of Obstetrics and Gynecology, Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, Via GB. Grassi 74, 20157 Milan, Italy; E-Mails:;Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, Via GB. Grassi 74, 20157 Milan, Italy; E-Mails:;Department of Chemistry, University of Milan, Via C.Golgi 19, 20133 Milan, Italy; E-Mails:

关键词: vaccine;    HIV-1;    adjuvant;    DC-SIGN;    innate immunity;    glycomimetic compounds;   

DOI  :  10.3390/v6020391

来源: mdpi

【 摘 要 】

The development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.